AXSM logo

Axsome Therapeutics Inc. (AXSM)

$135.95

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on AXSM

Market cap

$7.15B

EPS

-3.05

P/E ratio

--

Price to sales

11.36

Dividend yield

--

Beta

0.853296

Price on AXSM

Previous close

$137.01

Today's open

$136.36

Day's range

$134.61 - $137.49

52 week range

$123.00 - $260.19

Profile about AXSM

CEO

Herriot Tabuteau

Employees

925

Headquarters

New York, NY

Exchange

NASDAQ Global Market

Shares outstanding

52599985

Issue type

Common Stock

AXSM industries and sectors

Healthcare

Biotechnology & Life Sciences

News on AXSM

Axsome Therapeutics Sees AUVELITY Prescription Surge After Alzheimer's Agitation Launch

Axsome Therapeutics NASDAQ: AXSM executives said growth in new prescriptions for AUVELITY and an expanded sales team are positioning the company for further growth following the drug's launch for Alzheimer's disease agitation.

news source

MarketBeat • Nov 16, 2026

news preview

Axsome Therapeutics, Inc. (AXSM) Presents at UBS Global Biopharma Conference 2026 Transcript

Axsome Therapeutics, Inc. (AXSM) Presents at UBS Global Biopharma Conference 2026 Transcript

news source

Seeking Alpha • Nov 16, 2026

news preview

Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?

Axsome Therapeutics is experiencing rapid revenue growth driven by its portfolio of central nervous system treatments. Moderna is diversifying its messenger RNA platform into respiratory vaccines and oncology while facing significant net losses.

news source

The Motley Fool • Nov 14, 2026

news preview

Nasdaq Sell-Off: 2 Stocks to Buy on the Dip and Hold for 5 Years

Shopify could sustain strong revenue and earnings growth over the medium term by capitalizing on its AI-related initiatives. Axsome Therapeutics' most important drug is performing well, and the company is well-positioned to expand its lineup over the medium term.

news source

The Motley Fool • Nov 11, 2026

news preview

Axsome Therapeutics Tops $1 Billion Revenue Run Rate as AUVELITY Sales Surge

Axsome Therapeutics NASDAQ: AXSM reported $260 million in third-quarter revenue, driven by growth in its AUVELITY treatment for major depressive disorder and Alzheimer's disease agitation, executives said at the Guggenheim Healthcare Innovation Conference.

news source

MarketBeat • Nov 10, 2026

news preview

Axsome Therapeutics, Inc. (AXSM) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript

Axsome Therapeutics, Inc. ( AXSM ) 3rd Annual Guggenheim Healthcare Innovation Conference November 9, 2026 11:30 AM EST Company Participants Mark Jacobson - Chief Operating Officer Nick Pizzie - Chief Financial Officer Conference Call Participants Yatin Suneja - Guggenheim Securities, LLC, Research Division Presentation Yatin Suneja Guggenheim Securities, LLC, Research Division All right. I think we're live now.

news source

Seeking Alpha • Nov 9, 2026

news preview

Axsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027?

Axsome Therapeutics is generating rapid revenue growth from its expanding portfolio of central nervous system treatments. BioNTech maintains a massive cash position and virtually no debt while shifting its focus toward oncology and mRNA innovation.

news source

The Motley Fool • Nov 5, 2026

news preview

Axsome: 3 Key Takeaways for Long-Term Investors

Third-quarter revenue grew 52% year over year to $260 million. Management expects Auvelity to reach $8 billion in peak annual revenue.

news source

The Motley Fool • Nov 4, 2026

news preview

Axsome Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in November: Guggenheim 3rd Annual Healthcare Innovation Conference Fireside Chat: Monday, November 9, 2026, at 11:30 a.m. ET in Boston, MA 8th Annual Wolfe Research Healthcare Conference Investor Meetings: Tuesday, November 10, 2026, in New York, NY 2026 Truist BioPharma Symposium Investor Meetings: Thursday, November 12, 2026, in New York, NY UBS Global Biopharma Conference 2026 Fireside Chat: Monday, November 16, 2026, at 11:20 a.m.

news source

GlobeNewsWire • Nov 3, 2026

news preview

What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call

Axsome Therapeutics NASDAQ: AXSM reported third-quarter revenue growth of 52% year over year, driven primarily by continued expansion of AUVELITY sales in major depressive disorder and Alzheimer's disease agitation.

news source

MarketBeat • Nov 2, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Axsome Therapeutics Inc.

Open an M1 investment account to buy and sell Axsome Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in AXSM on M1